Optometry Times

Practical chairside advice Posting Policy:
Thank you for liking the official Optometry Times page. We're glad you're here.

We are committed to creating a community that encourages self-expression and mirrors the values of Optometry Times including respect for the rights, dignity, and property of others. We ask all fans to do their part to help us achieve the goal. In doing that, we ask you not to post content that:
-is threatening, abusive, obscene, indecent, or objectionable.
-is deceptive, false, or misleading
-violates the intellectual property rights of other people
-is illegal
-references a third party website or is self-promoting spam
-is inappropriate, offensive, or hateful
We reserve the right to remove any content or block users that violate our community guidelines, or that we determine are otherwise offensive to our community. All content must also comply with Facebook's policies as well. We would be sorry to see you go, but if you change your mind and no longer want to like our page, please feel free to "unlike" our page.

09/22/2026

In the second episode of the second season of The Independent Advantage, Maria Sampalis, OD, gives a resounding "absolutely not" when posited with the question of whether or not eye care providers will be replaced by artificial intelligence (AI). Eye care providers who are weary of AI implementation in their practice can learn more as the latest season of the video series progresses, which will discuss best practices for implementations, common misconceptions, and what benefits reside in utilizing AI tools.

Watch the latest episode here: https://hubs.li/Q04y4k0f0

09/19/2026

👁️This week in Optometry:
AMA resolution backs classifying myopia as a disease, aiming to expand insurance coverage for pediatric myopia control treatments.

Jem Martin, OD, discusses the accommodations and referrals any provider can offer, the red flags that should raise suspicion of CVI, and how the free TEACHCVI screening tool works in practice.

In the latest episode of The Independent Advantage, Maria Sampalis, OD, gives a resounding "absolutely not" when posited with the question of whether or not eye care providers will be replaced by AI.

In his latest column, Jeremy Walz, OD, FAAO, provides a practical guide for optometrists navigating comanagement of minimally invasive (or microinvasive) glaucoma surgery (MIGS) recovery.

A comparison of ETDRS charts using Latin letters, Tumbling E, and Landolt C optotypes found the alternatives are comparable to letter acuity at the population level.

Read the full coverage here: https://hubs.li/Q04xW3rc0

09/16/2026

Don’t miss this overview of what Xiidra offers patients with dry eye inflammation—early relief and long-term control.1

Take a deeper dive into the data at: https://hubs.li/Q04jdlcg0

Sponsored by Bausch & Lomb.

Please see full Prescribing Information for Xiidra at https://hubs.li/Q04jggxt0.

09/12/2026

👁️ This week's takeaways from Optometry Times:

In the latest episode of From Paper to Clinic, host Shah, OD, MS, FAAO, OD, MS, FAAO, is joined by Leonard Messner, OD, to discuss GLP-1s and idiopathic intracranial hypertension.

In the first episode of the second season of The Independent Advantage, Diana Canto-Sims, OD, chats with practice owner Maria Sampalis, OD, on why artificial intelligence has boomed in practice ownership spaces.

Lotfi Merabet, OD, PhD, MPH, discusses what his research on motion processing reveals about the neural roots of CVI and where diagnostic tools like neuroimaging and eye tracking are headed.

In her latest article for Optometry Times, Katherine Mastrota, OD, MS, FAAO, DipABO, discussed various periocular rehabilitation methods for dry eye treatment.

FDA accepts Nanoscope's biologics license application for MCO-010 in retinitis pigmentosa.

Read our full coverage here: https://hubs.li/Q04xhWG_0

09/05/2026

👁️ This week's clinical roundup from Optometry Times:

FDA grants De Novo nod to Avulux lens for migraine-associated photophobia.

Mile Brujic's, OD, FAAO, latest column overviews how advances in light-based technology are reshaping treatment of meibomian gland dysfunction.

Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.

Survey finds that fewer than 1 in 7 women link dry eye to perimenopause or menopause.

A recent study finds that Acoltremon ophthalmic solution 0.003% usage was associated with improved performance in visual acuity tasks.

Check out the full recap here:
https://hubs.li/Q04wMqvp0

08/31/2026

Mile Brujic, OD, FAAO, of Premier Vision Group shares two easy strategies for reducing digital eye strain as students head back to school, when many kids spend hours on tablets for schoolwork. He recommends holding devices at a bent-arm's length, roughly 16 inches from the eyes, to reduce strain during near work. He also highlights the 20-20-20 rule, encouraging patients to look away from screens every 20 minutes and focus on something 20 feet away for 20 seconds. Brujic notes these small, easy-to-remember habits benefit students and patients of all ages in practice.

Learn more about pediatric patient care on our website: https://hubs.li/Q04rqcqg0

08/29/2026

👁️ This week's clinical roundup from Optometry Times:

The FDA has expanded TearCare indication to include improvement of meibomian gland function in adult patients with evaporative dry eye disease due to MGD, making it the first treatment with this indication.

Bausch + Lomb announced phase 2 results of a dual-action lifitegrast/perfluorohexyloctane dry eye drop alongside positive phase 1b results for BL1332, a first-in-class TRPV1 antagonist for ocular surface pain.

The FDA accepts NDA for bimatoprost grenod in open angle glaucoma and OHT.

Roxanne Achong-Coan's, OD, FAAO, FIAOMC, FSLS, Dip CCLRT, latest column overviews the best optometric practices for reducing complications that commonly occur with contact lens use.

Recent study supports previous findings of highly aspherical lenslets spectacle lenses slowing myopia progression.

Check out the full recap here
https://hubs.li/Q04vMycV0

08/28/2026

We spoke to optometrists around the country about how they prepare for new and returning patients during the back to school season.

Watch the recap and full interviews here: https://hubs.li/Q04vL7yb0

08/27/2026

BREAKING: The FDA has accepted for review the new drug application (NDA) for Kowa Pharmaceuticals America’s K-911 (bimatoprost grenod; also known as NCX 470), an investigational once-daily topical monotherapy for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The agency assigned a Prescription Drug User Fee Act target action date of April 30, 2027, according to a news release. Additionally, Kowa anticipates a US commercial launch in the second half of 2027, contingent on approval.

Read more: https://hubs.li/Q04vzXvr0

08/25/2026

Carolyn Majcher, OD, FAAO, discussed her prediction for how physicians will implement changes in nAMD treatment following FDA approval of bevacizumab-vikg (Lytenava). She anticipates that cost will be the biggest factor in whether providers choose to prescribe Lytenava over off-label compounded bevacizumab. However, practices may favor Lytenava if it is priced only slightly higher than off-label, due to “confidence in the manufacturing and FDA approval regulatory processes”, according to Majcher.

For the full video, visit https://hubs.li/Q04tJt6q0

Address

24950 Country Club Boulevard, Ste 200
North Olmsted, OH
44070

Telephone

+14402438100

Website

https://www.optometrytimes.com/

Alerts

Be the first to know and let us send you an email when Optometry Times posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Optometry Times:

Want your business to be the top-listed Media Company in North Olmsted?